

Alwin Krämer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1548827/publications.pdf>

Version: 2024-02-01

64
papers

2,311
citations

257357

24
h-index

233338

45
g-index

65
all docs

65
docs citations

65
times ranked

4296
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1145-1158.	1.2	14
2	Severe Dysbiosis and Specific <i>Haemophilus</i> and <i>Neisseria</i> Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients. <i>Clinical Infectious Diseases</i> , 2022, 75, e1063-e1071.	2.9	18
3	Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 551-560.	1.5	4
4	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. <i>Journal of Hematology and Oncology</i> , 2022, 15, 60.	6.9	17
5	Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 153-162.	0.6	16
6	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. <i>British Journal of Cancer</i> , 2021, 124, 721-727.	2.9	5
7	HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 367-378.	1.9	42
8	Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 513-523.	1.1	4
9	A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. <i>Oncologist</i> , 2021, 26, e769-e779.	1.9	48
10	Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study. <i>Haematologica</i> , 2021, 106, 3100-3106.	1.7	14
11	The JmjC-domain protein NO66/RIOX-1 affects the balance between proliferation and maturation in acute myeloid leukemia. <i>Experimental Cell Research</i> , 2021, 402, 112566.	1.2	2
12	The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. <i>Haematologica</i> , 2021, 106, 3004-3007.	1.7	29
13	Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. <i>European Journal of Cancer</i> , 2021, 157, 179-189.	1.3	13
14	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. <i>Leukemia</i> , 2020, 34, 2903-2913.	3.3	38
15	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. <i>Blood Advances</i> , 2020, 4, 1131-1144.	2.5	102
16	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. <i>Blood</i> , 2020, 136, 823-830.	0.6	85
17	Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1629-1641.	1.0	2
18	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. <i>International Journal of Cancer</i> , 2020, 146, 3053-3064.	2.3	14

#	ARTICLE	IF	CITATIONS
19	Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial. <i>Blood</i> , 2020, 136, 10-11.	0.6	0
20	Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 1018-1021.	1.2	21
21	TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2619-2627.	3.3	19
22	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. <i>Cancers</i> , 2019, 11, 1309.	1.7	32
23	Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?. <i>Frontiers in Oncology</i> , 2019, 9, 402.	1.3	38
24	Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. <i>International Journal of Cancer</i> , 2019, 145, 2963-2973.	2.3	24
25	Micronucleus formation in human cancer cells is biased by chromosome size. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 392-395.	1.5	17
26	A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 583-587.	1.2	5
27	SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 795-799.	3.3	6
28	Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. <i>British Journal of Haematology</i> , 2019, 185, 595-598.	1.2	19
29	Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4120-4120.	0.8	2
30	High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia. <i>Blood</i> , 2019, 134, 3077-3077.	0.6	0
31	Diagnosis and management of metastatic neoplasms with unknown primary. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 199-206.	1.0	46
32	JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia Letter. <i>Cancer Research</i> , 2018, 78, 6339-6341.	0.4	3
33	Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. <i>Blood Advances</i> , 2018, 2, 2607-2618.	2.5	33
34	CD7 is expressed on a subset of normal CD34-positive myeloid precursors. <i>European Journal of Haematology</i> , 2018, 101, 318-325.	1.1	6
35	Enasidenib. <i>Recent Results in Cancer Research</i> , 2018, 212, 187-197.	1.8	4
36	Prediction of acute myeloid leukaemia risk in healthy individuals. <i>Nature</i> , 2018, 559, 400-404.	13.7	617

#	ARTICLE	IF	CITATIONS
37	Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions.. Journal of Clinical Oncology, 2018, 36, e24162-e24162.	0.8	6
38	PPM1D Mutations Are Rare in De Novo and Therapy-Related Acute Myeloid Leukemia. Blood, 2018, 132, 1472-1472.	0.6	2
39	Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability. European Journal of Medicinal Chemistry, 2017, 130, 240-247.	2.6	14
40	Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. Blood, 2017, 129, 1333-1342.	0.6	57
41	Clinical impact of <scp>KMT</scp>2C and <scp>SPRY</scp>4 expression levels in intensively treated younger adult acute myeloid leukemia patients. European Journal of Haematology, 2017, 99, 544-552.	1.1	5
42	Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in Cancer. Cell Reports, 2017, 20, 1906-1920.	2.9	49
43	Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia. Journal of Physical Education and Sports Management, 2016, 2, a001123.	0.5	2
44	Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization. Cancer Research, 2016, 76, 6690-6700.	0.4	24
45	Centrosome amplification, chromosomal instability and cancer: mechanistic, clinical and therapeutic issues. Chromosome Research, 2016, 24, 105-126.	1.0	59
46	Gene-targeted CEP164-deficient cells show a ciliation defect with intact DNA repair capacity. Journal of Cell Science, 2016, 129, 1769-74.	1.2	36
47	Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget, 2016, 7, 44322-44329.	0.8	47
48	Germline genetics of cancer of unknown primary (CUP) and its specific subtypes. Oncotarget, 2016, 7, 22140-22149.	0.8	12
49	Marker Chromosomes Can Arise from Chromothripsis and Predict Adverse Prognosis in Acute Myeloid Leukemia. Blood, 2016, 128, 2869-2869.	0.6	0
50	Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial. British Journal of Haematology, 2015, 171, 710-719.	1.2	30
51	Cep63 Recruits Cdk1 to the Centrosome Letter. Cancer Research, 2015, 75, 777-778.	0.4	2
52	Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood, 2014, 124, 13-23.	0.6	139
53	Patients With Cancer of Unknown Primary. Deutsches Ärzteblatt International, 2014, 111, 481-7.	0.6	25
54	Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soramf Trial. Blood, 2014, 124, 6-6.	0.6	34

#	ARTICLE	IF	CITATIONS
55	Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. <i>Oncotarget</i> , 2014, 5, 10237-10250.	0.8	22
56	Clonal Heterogeneity As Detected by Metaphase Karyotyping Is an Indicator of Poor Prognosis in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 3898-3905.	0.8	63
57	Pre-Transplant Weight Loss and Total Serum Protein Predict Relapse Of Acute Myeloid Leukaemia After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3314-3314.	0.6	0
58	Efficacy Of Azacitidine Versus Low-Dose Cytarabine In Patients With Acute Myeloid Leukemia - A Retrospective Single Center Experience. <i>Blood</i> , 2013, 122, 3974-3974.	0.6	0
59	Centrosome clustering and chromosomal (in)stability: A matter of life and death. <i>Molecular Oncology</i> , 2011, 5, 324-335.	2.1	98
60	GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Growth in Vivo.. <i>Blood</i> , 2008, 112, 1639-1639.	0.6	0
61	JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. <i>Lancet Oncology</i> , The, 2007, 8, 658-660.	5.1	72
62	Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma: Proof of Common Clonal Origin. <i>Chinese-German Journal of Clinical Oncology</i> , 2004, 3, 81.	0.1	0
63	Polymorphisms of the tumor necrosis factor- β gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. <i>Blood</i> , 2002, 100, 2263-2265.	0.6	91
64	Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. <i>British Journal of Haematology</i> , 2001, 115, 605-608.	1.2	62